A CCR5 Antagonist That is Dosed Once Daily Could Earn an 18 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe, According to a New Report from Decision Resources
WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed infectious disease specialists identify a therapy's effect on the ability to achieve viral load suppression in treatment-naive patients as the attribute that most influences their prescribing decisions in HIV. Surveyed specialists indicate they are highly satisfied with Gilead/Bristol Myers Squibb's Atripla and Merck's Isentress in this attribute.
The new report entitled HIV: Opportunity lies for Drug Developers in Integrase Inhibitors and Next Generation CCR5 Antagonists finds that a novel drug in the CCR5 antagonist class that is dosed once daily and achieves maximum physician expectations would earn an 18 percent patient share in HIV in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European infectious disease specialists.
In 2008, Decision Resources' proprietary clinical gold standard for HIV was Merck's Isentress/Gilead's Truvada. Based on expert opinion, Isentress/Truvada will retain clinical gold standard status through 2017, owing to its balance of efficacy, novel mechanisms of action and safety. Although some therapies in development for HIV hold promise, most have efficacy, safety and tolerability, and/or delivery features that interviewed thought leaders believe are inferior when compared with Isentress/Truvada.
"Experts we surveyed rated Isentress plus Truvada as one of the safest antiretroviral regimens available," said Decision Resources Analyst Jose Avalos, Ph.D. "Furthermore, interviewed specialists believe Isentress' novel mechanism of action provides advantages in highly treatment experienced patients."
About the Report
HIV: Opportunity lies for Drug Developers in Integrase Inhibitors and Next Generation CCR5 Antagonists is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved